References
- Love R R, Leventhal H, Easterling D V, et al. Side effects and emotional distress during cancer chemotherapy. Cancer 1989; 63: 604–612
- Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25(Suppl 1)1–7
- Hesketh P J, Gandara D R. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991; 83: 613–620
- Alba E, Bastus R, De Andres L, et al. Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology 1989; 63: 604–612
- Kris M G, Gralla R J, Clark R A, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379–1384
- Morrow G R. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68: 585–588
- Miner W D, Sanger G J. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497
- Chevallier B. The control of acute cisplatin-induced emesis—A comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993; 68: 176–180
- Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990; 26(Suppl 1)S33–S36
- Cupissol D R, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990; 26: S23–S27
- Falkson H C, Falkson C I, Falkson G. High versus low dose granisetron, a selective 5-HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting. Invest New Drugs 1990; 8: 407–409
- De Mulder P HM, Seynaeve C, Vermorken J B, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–840
- Grunberg S M, Stevenson I X, Russell C A, et al. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989; 7: 1137–1141
- Jantunen I T, Muhonen T T, Kataja V V, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study. Eur J Cancer 1993; 29A: 1669–1672
- Kamanabrou D. Intravenous granisetron-Establishing the optimal dose. Eur J Cancer 1992; 28A(Suppl 1)S6–S11
- Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamines (serotonin) receptor antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–821
- Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cyto-static-induced emesis. Eur J Cancer 1990; 26(Suppl 1)S28–S32
- Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242–1248
- Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675–678
- Sledge G W, Jr, Einhorn L, Nagy C, et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992; 70: 2524–2528
- Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990; 26(Suppl 1)S15–S19
- Navari R M, Kaplan H G, Gralla R J, et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994; 12: 2204–2210
- Blijham G H. on behalf of the Granisetron Study Group: Does granisetron remain effective over multiple cycles?. Eur J Cancer 1992; 28A(Suppl 1)S17–21
- Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: A review. Ann Oncol 1991; 2: 107–114